Last reviewed · How we verify
CD-4 guided therapy interruption
CD4-guided therapy interruption is a treatment strategy that involves periodically stopping antiretroviral therapy in HIV patients based on CD4+ T cell count thresholds to reduce long-term drug exposure while maintaining immune control.
CD4-guided therapy interruption is a treatment strategy that involves periodically stopping antiretroviral therapy in HIV patients based on CD4+ T cell count thresholds to reduce long-term drug exposure while maintaining immune control. Used for HIV infection (CD4-guided structured treatment interruption).
At a glance
| Generic name | CD-4 guided therapy interruption |
|---|---|
| Sponsor | Hospital Clinic of Barcelona |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
This approach uses CD4+ T cell counts as a biomarker to guide when to interrupt antiretroviral therapy (ART) in HIV-infected patients. The strategy aims to minimize cumulative antiretroviral drug exposure and associated toxicities while relying on the patient's residual immune function to control viral replication during treatment interruption periods. Therapy is resumed when CD4 counts decline below a predetermined threshold.
Approved indications
- HIV infection (CD4-guided structured treatment interruption)
Common side effects
- Viral rebound
- CD4 decline
- Opportunistic infections
- Immune reconstitution inflammatory syndrome (IRIS)
Key clinical trials
- Safety and Effectiveness of Short-Term Anti-HIV Drug Therapy for Recent HIV-1 Infection (NA)
- Long Term Treatment Interruptions (PHASE3)
- Strategies of Interruption/Reinitiation of Antiretroviral Therapy in HIV-Infected Patients With Lipodystrophy (PHASE4)
- Staccato: A Trial of CD4 Guided Treatment Interruption, Compared to Continuous Treatment, for HIV Infection (NA)
- BASTA Study on STI in HIV Infected Patients (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CD-4 guided therapy interruption CI brief — competitive landscape report
- CD-4 guided therapy interruption updates RSS · CI watch RSS
- Hospital Clinic of Barcelona portfolio CI